Targeted Lung Cancer Therapies

Amivantamab-vmjw with carboplatin and pemetrexed is approved by the USFDA for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations

On September 19, 2024, the Food and Drug Administration sanctioned amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in conjunction with carboplatin and pemetrexed for adult patients diagnosed with ...
targeted-lung-cancer-therapies

Scan the code

Tag: Targeted Lung Cancer Therapies

Home / Targeted Lung Cancer Therapies

Categories

Amivantamab-vmjw with carboplatin and pemetrexed is approved by the USFDA for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations

Information

Treatment

United States

Romania

India

Cambodia

Shanghai

Beijing

Hong Kong